86 filings
Page 2 of 5
8-K
g8d ma620j5omc69p9u2
8 Nov 21
Reata Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
6:45am
8-K
qyjcfpgm
22 Oct 21
Departure of Directors or Certain Officers
6:02am
8-K
6k10i3pldyt7s 2zhk
20 Aug 21
Entry into a Material Definitive Agreement
4:19pm
8-K
bgxkv8jw8 akn7asxrn6
9 Aug 21
Reata pharmaceuticals, inc. announces SECOND quarter 2021 financial RESULTS and provides an update on CLINICAL DEVELOPMENT programs
4:06pm
8-K
08zzy 3s23
23 Jun 21
Departure of Directors or Certain Officers
4:15pm
8-K
5q5w3tctn w8lscp
11 Jun 21
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
smttx 425
6 May 21
Reata pharmaceuticals, inc. announces First quarter 2021 financial RESULTS and provides an update on CLINICAL DEVELOPMENT programs
6:50am
8-K
bg2kw8q
15 Apr 21
REATA Announces THE APPOINTMENTs OF Christy J. Oliger and Shamim Ruff TO ITS BOARD OF DIRECTORS
6:50am
8-K
31gp6aik11vldu4j8qmr
1 Mar 21
Reata pharmaceuticals, inc. announces FOURTH quarter AND FULL YEAR 2020 financial RESULTS and provides an update on CLINICAL DEVELOPMENT programs
6:40am
8-K
tmkqd5l9trwdm qwj2i
11 Jan 21
Regulation FD Disclosure
6:30am
8-K
2zqp0l3d
3 Dec 20
Entry into a Material Definitive Agreement
4:45pm
8-K
0g58yg911rmlnje6
9 Nov 20
Vinny Jindal; Reata Pharmaceuticals Inc.; VP of Strategy
5:30pm
8-K
nqjg 588ykdehi6dqu0
9 Nov 20
Reported positive year 2 data from the pivotal CARDINAL study of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome
6:51am
8-K
onazymws8ol
27 Aug 20
Departure of Directors or Certain Officers
8:00am
8-K
u29e940b
10 Aug 20
PRE-NDA (NEW DRUG APPLICATION) MEETING GRANTED for Bardoxolone
6:51am
8-K
w0nd3rux
30 Jul 20
Reata Announces the Appointment of Martin W. Edwards, M.D. to Its Board of Directors
9:16pm
8-K
8svskin5mtaswvy0g
7 Jul 20
Reata Announces promotion and New hires for key leadership roles
6:50am
8-K
lanwoaaze0 x0o8pjb
24 Jun 20
Reata PHARMACEUTICALS, Inc. CLOSES $350 Million strategic investment from blackstone life sciences
10:23am
8-K
ueymm465cj
11 Jun 20
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
4k6wry1s51 w5f
11 Jun 20
Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350 Million Strategic Investment
9:26am